title: Comment on Monnier et al. Magnitude of the dawn phenomenon and its impact on the overall glucose exposure in type 2 diabetes: is this of concern? Diabetes Care 2013;36:4057-4062.
authors: Merck A/S, Ballerup, Denmark richard.carr@merck.com.
authors: Richard D
authors: RD
authors: Carr
authors: Merck & Co., Inc., Whitehouse Station, NJ.
authors: Charles M
authors: CM
authors: Alexander
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D002940:Circadian Rhythm; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004032:Diet; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D008297:Male
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents